A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

This study is testing a new eye drop treatment for dry eye disease caused by Sjögren's syndrome, a condition where the immune system attacks the glands that produce tears and saliva. The trial is a randomized, double-masked (neither participants nor researchers know who gets which treatment), controlled Phase II study. **You may be eligible if...** - You are aged 18–75 and have had Sjögren's syndrome for at least 3 months - You are only using artificial tears as your current dry eye treatment - Your dry eye symptoms are moderate to severe (Global SANDE score ≥ 40) - Your current systemic medications have been stable for at least one month **You may NOT be eligible if...** - You use prescription eye drops (other than artificial tears) for dry eye - You have recently changed your systemic medications - You are pregnant or breastfeeding - You have active eye infections or other significant eye conditions Talk to your doctor to see if this trial is right for you.